Single injection of ONO-1301-loaded PLGA microspheres directly after ischaemia reduces ischaemic damage in rats subjected to middle cerebral artery occlusion

Journal of Pharmacy and Pharmacology

Volumn 64, Issue 3, 2012, Pages 353-359

  Hazekawa, Mai ^a   Sakai, Yoshiki ^b   Yoshida, Miyako ^a   Haraguchi, Tamami ^a   Uchida, Takahiro ^a  

^a MUKOGAWA WOMEN'S UNIVERSITY   (Japan)

^b ONO PHARMACEUTICAL CO   (Japan)

Author keywords

MCAO; neuroprotective effect; oedema; PLGA microspheres; prostacyclin

Indexed keywords

7,8 DIHYDRO 5 [2 [[ALPHA (3 PYRIDYL)BENZYLIDENE]AMINOOXY]ETHYL] 1 NAPHTHYLOXYACETIC ACID; MICROSPHERE; POLYGLACTIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN DAMAGE; BRAIN EDEMA; BRAIN INFARCTION SIZE; BRAIN ISCHEMIA; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG FORMULATION; DRUG RELEASE; ENCAPSULATION; LOW DRUG DOSE; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; NEUROPROTECTION; NONHUMAN; PARTICLE SIZE; RAT; SCORING SYSTEM; SINGLE DRUG DOSE;

EID: 84857042236     PISSN: 00223573     EISSN: 20427158     Source Type: Journal    
DOI: 10.1111/j.2042-7158.2011.01416.x     Document Type: Article

References (26)

1. Tanouchi T, et al,. Highly selective inhibitors of thromboxane synthetase. 2 Pyridine derivatives. J Med Chem 1981; 24: 1149-1155. (Pubitemid 12208770)
2. Kataoka M, et al,. A long-acting prostacyclin agonist with thromboxane inhibitory activity for pulmonary hypertension. Am J Respir Crit Care Med 2005; 172: 1575-1580. (Pubitemid 43076548)
3. Obata H, et al,. Single injection of a sustained-release prostacyclin analog improves pulmonary hypertension in rats. Am J Respir Crit Care Med 2008; 177: 195-201.
4. Murakami S, et al,. Prostacyclin agonist with thromboxane synthase inhibitory activity (ONO-1301) attenuates bleomycin-induced pulmonary fibrosis in mice. Am J Physiol Lung Cell Mol Physiol 2006; 290: 59-65.
5. Okano Y, et al,. Orally active prostacyclin analogue in primary pulmonary hypertension. Lancet 1997; 349: 1365. (Pubitemid 27197541)
6. Nagaya N, et al,. Effect of orally active prostacyclin analogue on survival of outpatients with primary pulmonary hypertension. J Am Coll Cardiol 1999; 34: 1188-1192. (Pubitemid 29500559)
7. Olschewski H, et al,. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002; 347: 322-329. (Pubitemid 34815354)
8. Simonneau G, et al,. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary hypertension: a double-blind randomized controlled trial. Am J Respir Crit Care Med 2002; 165: 800-804. (Pubitemid 34229650)
9. Ike O, et al,. Biodegradation and antitumour effect of adriamycin-contapoly (L-lactic acid) microspheres. Biomaterials 1991; 12: 757-762.
10. Umeki N, et al,. Preparation and evaluation of biodegradable microspheres containing a new potent osteogenic compound and new synthetic polymers for sustained release. Int J Pharm 2010; 392: 42-50.
11. Grände PO, et al,. Low-dose prostacyclin in treatment of severe brain trauma evaluated with microdialysis and jugular bulb oxygen measurements. Acta Anaesthesiol Scand 2000; 44: 886-894.
12. Naredi S, et al,. An outcome study of severe traumatic head injury using the 'Lund therapy' with low-dose prostacyclin. Acta Anaethesiol. Scand. 2001; 45: 402-426.
13. Ginsberg MD,. Adventures in the pathophysiology of brain ischemia: penumbra, gene expression, neuroprotection: the 2002 Thomas Willis Lecture. Stroke 2003; 34: 214-223. (Pubitemid 36070826)
14. Belayev L, et al,. Middle cerebral artery occlusion in the rat by intraluminal suture: neurological and pathological evaluation of an improved model. Stroke 1996; 27: 1616-1623. (Pubitemid 26295914)
15. Hayakawa K, et al,. Delayed treatment with minocycline ameliorates neurologic impairment through activated microglia expressing a high-mobility group box1-inhibiting mechanism. Stroke 2008; 39: 951-958. (Pubitemid 351619558)
16. Hazekawa M, et al,. Preparation of ONO-1301-loaded PLGA microspheres and their effect on nerve conduction velocity. J Pharm Pharmacol 2011; 63: 362-368.
17. Yamamoto M, et al,. Behavioral changes after focal cerebral ischemia by left middle cerebral artery occlusion in rats. Brain Res 1988; 452: 323-328.
18. Tamura A, et al,. Focal cerebral ischemia in the rat. 1: Description of technique and early neuropathological consequences following middle cerebral artery occlusion. J Cereb Blood Flow Metab 1981; 1: 53-60. (Pubitemid 12230166)
19. Choi JM, et al,. Neuroprotective effect of cilostazol against focal cerebral ischemia via antiapoptotic action in rats. J Pharmacol Exp Ther 2002; 300: 787-793. (Pubitemid 34164980)
20. Xing B, et al,. Ischemic post-conditioning protects brain and reduces inflammation in a rat model of focal cerebral ischemia/reperfusion. J Neurochem 2008; 105: 1737-1745. (Pubitemid 351678501)
21. Pinto E, et al,. Feasibility of localized immunosuppressioon: 2. PLA microspheres for the sustained local delivery of a soft immunosuppressant. Phatmazie 2010; 65: 429-435.
22. Yoshikawa N,. Relationship between standing balance and symmetry measurements in patients following recent strokes (3 weeks) or older strokes (6 months). Rigaku Ryoho Janaru 2005; 39: 199-199.
23. Chao X, et al,. Neuroprotective effect of osthole against acute ischemic stroke on middle cerebral ischemia occlusion in rats. Brain Res 2010; 1363: 206-211.
24. McCabe C, et al,. Differences in the evolution of the ischemic penumbra in stroke-prone spontaneously hypertensive and Wistar-Kyoto rats. Stroke 2009; 40: 3864-3868.
25. Reinstrup P, Nordström CH,. Prostacyclin infusion may prevent secondary damage in precontusional brain tissue. Neurocrit Care 2011; 14: 441-446.
26. Lipton P,. Ischemic cell death in brain neurons. Physiol Rev 1999; 79: 1431-1568. (Pubitemid 29473320)